NCT03440450View on ClinicalTrials.gov

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

May 15, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid TumorsBiliary Tract Cancer
Interventions
DRUG

FF-10832 Gemcitabine Liposome Injection

FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Trial Locations (7)

37203

Sarah Cannon Research Institute, Nashville

77030

MD Anderson Cancer Research Center, Houston

80218

Sarah Cannon Research Institute, Denver

85258

Honor Health Research Institute, Scottsdale

85719

University of Arizona Cancer Center, Tucson

92658

Hoag Memorial Hospital Comprehensive Cancer Center, Newport Beach

98101

Virginia Mason Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Fujifilm Pharmaceuticals U.S.A., Inc.

INDUSTRY